A novel once-daily protease inhibitor

Drugs of Today

Volumn 40, Issue 11, 2004, Pages 901-912

  Piliero, Peter J ^a  

^a ALBANY MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; AMPRENAVIR; ANTIRETROVIRUS AGENT; ATAZANAVIR; CD4 ANTIGEN; CHOLESTEROL; CLARITHROMYCIN; CYTOCHROME P450 3A; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; INDINAVIR; KETOCONAZOLE; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RIFABUTIN; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR DISOPROXIL; ZALCITABINE; ZIDOVUDINE; OLIGOPEPTIDE; PYRIDINE DERIVATIVE;

ABDOMINAL PAIN; AREA UNDER THE CURVE; CARDIOVASCULAR RISK; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIARRHEA; DISEASE ASSOCIATION; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG APPROVAL; DRUG EFFICACY; DRUG MARKETING; DRUG POTENCY; DYSLIPIDEMIA; FLU LIKE SYNDROME; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; INFECTION; JAUNDICE; LIPID BLOOD LEVEL; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; NAUSEA; NEUROLOGIC DISEASE; PERIPHERAL NEUROPATHY; PROTEINASE INHIBITION; RASH; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; VIRUS LOAD; VOMITING; BIOAVAILABILITY; CONTROLLED CLINICAL TRIAL; DRUG COMBINATION; HALF LIFE TIME; INTESTINE ABSORPTION; MALE; METABOLISM; RANDOMIZED CONTROLLED TRIAL;

AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; DRUG THERAPY, COMBINATION; HALF-LIFE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; INTESTINAL ABSORPTION; MALE; OLIGOPEPTIDES; PYRIDINES; RANDOMIZED CONTROLLED TRIALS;

EID: 11844288256     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2004.40.11.872579     Document Type: Review

References (41)

1. Yeni, P.G., Hammer, S.M., Carpenter, C.C. et al. Antiretroviral treatment for adult HIV infection in 2002: Updated recommendations of the International AIDS Society-USA Panel. JAMA 2002, 288: 222-35.
2. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. 10 November 2003. www.aidsinfo.nih.gov.
3. Prous Science Drug R&D Backgrounders: AIDS (online publication). Updated February 4, 2004.
4. Paterson, D.L., Swindells, S., Mohr, J. et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infections. Ann Intern Med 2000, 133: 21-30
5. Bristol-Myers Squibb Company. BMS-232632: Atazanavir briefing document May-2003 [online]. Available from URL: http://www.fda.gov/ohrms/ dockets/ac/03/briefing/3950B1_01_BristolMyers Squibb-Atazanavir.pdf [Accessed September 2003].
6. Robinson, B.S., Riccardi, K.A., Gong, Y.-F. et al. BMS-232632, a highly potent human immunodeficiency virus protease inhibitor that can be used in combination with other available antiretroviral agents. Antimicrob Agents Chemother 2000, 44: 2093-9.
7. Gong, Y.-F., Robinson, B.S., Rose, R.E. et al. In vitro resistance profile of the human immunodeficiency virus type 1 protease inhibitor BMS-232632. Antimicrob Agents Chemother 2000, 44: 2319-26.
8. Colonno, R.J., Thiry, A., Limoli, K., Parkin, N. Activities of atazanavir (BMS-232632) against a large panel of human immunodeficiency virus type 1 clinical isolates resistant to one or more approved protease inhibitors. Antimicrob Agents Chemother 2003, 47: 1324-33.
9. Colonno, R.J., Friberg, J., Rose, R.E., Lam, E., Parkin, N. Identification of amino acid substitutions correlated with reduced atazanavir susceptibility in patients treated with atazanavir-containing regimens. Antivir Ther 2002, 7 (2, Suppl. 1): Abst. 4.
10. Colonno, R., Rose, R., Cianci, C., Aldrovandi, G., Parkin, N., Friborg, J. Emergence of atazanavir resistance and maintenance of susceptibility to other PIs is associated with an 150L substitution in HIV protease. 10th Conf Retroviruses Opportunistic Infect (Feb 10-14, Boston) 2003, Abst. 597.
11. O'Mara, E.M., Smith, J., Olsen, S.J., Tanner, T., Schuster, A.E., Kaul, S. BMS-232632: Single-oral dose-safety and pharmacokinetic study in healthy volunteers. 38th Intersci Conf Antimicrob Agents Chemother (Sept 24-27, San Diego) 1998, Abst. I-242.
12. O'Mara, E., Mummaneni, V., Randall, D. et al. BMS-232632: A summary of multiple-dose pharmacokinetic, food effect, and drug interaction studies in healthy subjects. 7th Conf Retroviruses Opportunistic Infect (Jan 30-Feb 2, San Francisco) 2000, Abst. 504.
13. O'Mara, E., Piliero, P., Drusano, G. et al. A preliminary pharmacokinetic and pharmacodynamic evaluation of the HIV protease inhibitor BMS-232632 in a protease inhibitor-naïve HIV+ population. AIDS 2000, 14 (Suppl. 4): Abst. P9.
14. O'Mara, E.M., Smith, J., Olsen, S.J., Tanner, T., Schuster, A.E., Kaul, S. BMS-232632: Single-oral dose-safety and pharmacokinetic study in healthy volunteers. 38th Intersci Conf Antimicrob Agents Chemother (Sept 24-27, San Diego) 1998, Abst. I-242.
15. Agarwala, S., Grasela, D., Child, M., Geraldes, M., Geiger, M., and O'Mara, E. Characterization of the steady-state pharmacokinetic (PK) profile of atazanavir (ATV) beyond the 24-hour dosing interval. Antivir Ther 2003, 8 (Suppl. 1): S422.
16. O'Mara, E.M., Randall, D., Mummaneni, V. et al. Steady-state pharmacokinetic interaction study between BMS-232632 and ketoconazole in healthy subjects. 40th Intersci Conf Antimicrob Agents Chemother (Sept 17-20, Toronto) 2000, Abst. I-1646.
17. O'Mara, E., Mummaneni, V., Bifano, M. et al. Steady-state pharmacokinetic interaction study between BMS-232632 and ritonavir in healthy subjects. 8th Conf Retroviruses Opportunistic Infect (Feb 4-8, Chicago) 2001, Abst. 740.
18. Preston, S., Piliero, P., O'Mara, E. et al. Evaluation of steady-state interaction between atazanavir (ATV) and efavirenz (EFV). 9th Conf Retroviruses Opportunistic Infect (Feb 24-28, Seattle) 2002, Abst. 443-W.
19. O'Mara, E., Agarwala, S., Randall, M. et al. Steady-state pharmacokinetic interaction study of atazanavir (ATV) with efavirenz (EFV) and ritonavir (RTV) in healthy subjects. 9th Conf Retroviruses Opportunistic Infect (Feb 24-28, Seattle) 2002, Abst. 444-W.
20. Randall, D., Agarwala, S., Mummaneni, V., Geraldes, M., Giordano, M., O'Mara, E. Tissue compartment concentrations of atazanavir (ATV) in cerebrospinal fluid, seminal fluid and plasma in HIV + subjects. 42nd Intersci Conf Antimicrob Agents Chemother (Sept 27-30, San Diego) 2002, Abst. H-1711.
21. O'Mara, E., Cirincione, B., Mummaneni, V., Grasela, T., Grasela, D. Population pharmacodynamic (PD) assessment of the safety and anti-retroviral activity of BMS-232632. 41st Intersci Conf Antimicrob Agents Chemother (Dec 16-19, Chicago) 2001, Abst. A-507 + Poster.
22. O'Mara, E., Randall, D., Stoltz, R., Geraldes, M., Mummaneni, V. BMS-232632: A prospective study of age and gender effects on the single-dose pharmacokinetics in healthy volunteers. 1st IAS Conf HIV Pathog Treat (Jul 8-11, Buenos Aires) 2001, Abst. 350.
23. Agarwala, S., Russo, R., Mummaneni, V., Randall, D., Geraldes, M., O'Mara, E. Steady-state pharmacokinetic (PK) interaction study of atazanavir (ATV) with ritonavir (RTV) in healthy subjects. 42nd Intersci Conf Antimicrob Agents Chemother (Sept 27-30, San Diego) 2002, Abst. H-1716.
24. Mummaneni, V., Randall, D., Chabuel, D., Geraldes, M., O'Mara, E. Steady-state pharmacokinetic (PK) interaction study of atazanavir (ATV) with clarithromycin (CLR) in healthy subjects. 42nd Intersci Conf Antimicrob Agents Chemother (Sept 27-30, San Diego) 2002, Abst. H-1717.
25. Agarwala, S., Mummaneni, V., Randall, D., Geraldes, M., Stoltz, R., O'Mara, E. Pharmacokinetic (PK) effect of rifabutin (RIF) on atazanavir (ATV) with and without ritonavir (RTV) in healthy subjects. 9th Conf Retroviruses Opportunistic Infect (Feb 24-28, Seattle) 2002, Abst. 445-W.
26. Mummaneni, V., Randall, D., Geraldes, M., Uderman, H., O'Mara, E. Steady-state pharmacokinetic (PK) interaction study of atazanavir (ATV) with lamivudine (3-TC) and zidovudine (ZDV) in healthy subjects. 42nd Intersci Conf Antimicrob Agents Chemother (Sept 27-30, San Diego) 2002, Abst. H-1713.
27. Taburet, A.M., Piketty, C., Gérard, L. et al. Pharmacokinetic parameters of atazanavir/ritonavir when combined to tenofovir in HIV infected patients with multiple treatment failures: A sub-study of puzzle-2-ANRS 107 trial. 10th Conf Retroviruses Opportunistic Infect (Feb 10-14, Boston) 2003, Abst. 537.
28. Jackett, D., Child, M., Agarwala, S. et al. Atazanavir: A summary of two pharmacokinetic drug interaction studies in healthy subjects. 10th Conf Retroviruses Opportunistic Infect (Feb 10-14, Boston) 2003, Abst. 543.
29. Clotet, B., Negredo, E. HIV protease inhibitors and dyslipidemia. AIDS Rev 2003, 5: 19-24.
30. Piliero, P., Cahn, P., Pantaleo, G., et al. Atazanavir: A once-daily protease inhibitor with a superior lipid profile: Results of clinical trials beyond week 48. 9th Conf Retroviruses Opportunistic Infect (Feb 24-28, Seattle) 2002, Abst. 706-T.
31. O'Mara, E., Mummaneni, V., Burchell, B. et al. Relationship between uridine diphosphate-glucuronosyl transferase 1A1 genotype and bilirubin elevations in healthy subjects receiving BMS-232632 and saquinavir. 40th ICAAC, Toronto, Canada, Sept 17-20, 2000, Abst. 1645.
32. Sanne, I., Piliero, P., Squires, K., Thiry, A., Schnittman, S. Results of a phase 2 clinical trial at 48 weeks (AI424-007): A dose-ranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naive subjects. J Acquir Immune Defic Syndr (JAIDS) 2003, 32: 18-29.
33. Haas, D.W., Zala, C., Schrader, S. et al. Therapy with atazanavir plus saquinavir in patients failing highly active antiretroviral therapy: A randomized comparative trial. AIDS 2003; 17: 1330-49.
34. Pantaleo, G., Sanne, I., Cahn, P. et al. Atazanavir (BMS-232632): 48-week safety and efficacy vs. nelfinavir, each in combination with stavudine and lamivudine, in treatment-naive, HIV-positive subjects (AI424-008). 8th Eur Conf CNn Aspects Treat HIV Infect (Oct 28-31, Athens) 2001, Abst. 223 + Poster.
35. Cahn, P., Piliero, P., Giordano, M., Thiry, A., Schnittman, S. Atazanavir (ATV): Antiretroviral efficacy in HIV-infected patients co-infected with hepatitis B and/or C viruses (HBV, HCV). 42nd Intersci Conf Antimicrob Agents Chemother (Sept 27-30, San Diego) 2002, Abst. H-1730.
36. Murphy, R., Pokrovsky, V., Rozenbaum, W. et al. Long-term efficacy and safety of atazanavir with stavudine and lamivudine in patients previously treated with nelfinavir or ATV: 108-Week results of BMS study 008/044. 10th Conf Retroviruses Opportunistic Infect (Feb 10-14, Boston) 2003, Abst. 555 + Poster.
37. Squires, K.E., Thiry, A., Giordano, M. Atazanavir (ATV) QD and efavirenz (EFV) QD with fixed-dose ZDV + 3TC: Comparison of antiviral efficacy and safety through Wk 24 (AI424-034). 42nd Intersci Conf Antimicrob Agents Chemother (Sept 27-30, San Diego) 2002, Abst. H-1076 + Poster.
38. Rivero, A., Delfraissy, J.-F., Yakovlev, A., Thiry, A., Schrader, S., Giordano, M. Atazanavir QD and efavirenz QD with fixed-dose ZDV + 3TC: Absence of insulin resistance through week 24 (AI424-034). 6th Int Congr Drug Ther HIV Infect (Nov 17-21, Glasgow) 2002, Abst. P132.
39. Nieto-Cisneros, L., Zala, C., Fessel, W.J. et al. Antiviral efficacy, metabolic changes and safety of atazanavir (ATV) versus lopinavir/ritonavir (LPV/RTV) in combination with two NRTIs in patients who have experienced virological failure with prior PI-containing regimen(s): 24-week results from BMS AI424-043. Antivir Ther 2003, 8 (Suppl. 1): Abst. 117.
40. Badaro, R., De Jesus, E., Lazzarin, A. et al. Efficacy and safety of atazanavir (ATV) with ritonavir (RTV) or saquinavir (SQV) versus lopinavir/ritonavir (LPV/RTV) in combination with tenofovir (TFV) and one NRTI in patients who have experienced virologic failure to multiple HAART regimens: 24-week results from BMS AI424-045. Antivir Ther 2003, 8 (Suppl. 1): Abst. 118
41. Markowitz, M., Simon, V., Vasan, S. et al. 48-Week results of an atazanavir-based QD regimen in patients switching from BID PI-based HAART. Antivir Ther 2003, 8 (Suppl. 1): Abst. 543.